Transient expression of Ebola virus (EBOV) glycoprotein GP causes downregulation of surface proteins, cell rounding and detachment, a phenomenon believed to play a central role in the pathogenicity of the virus. In this study, evidence that moderate expression of GP does not result in such morphological changes was provided. It was shown that GP continuously produced in 293T cells from the Kunjin virus replicon was correctly processed and transported to the plasma membrane without affecting the surface expression of β1 and α5 integrins and major histocompatibility complex I molecules. The level of GP expression in Kunjin replicon GP-expressing cells was similar to that observed in cells infected with EBOV early in infection and lower than that produced in cells transfected with plasmid DNA, phCMV-GP, expressing GP from a strong promoter. Importantly, transient transfection of Kunjin replicon GP-expressing cells with GP-coding plasmid DNA resulted in overexpression of GP, which lead to the downregulation of surface molecules and massive rounding and detachment of transfected cells. Here, it was also demonstrated that cell rounding and downregulation of the surface markers are the late events in EBOV infection, whereas synthesis and massive release of virus particles occur at early steps and do not cause significant cytotoxic effects. These findings indicate that the synthesis of EBOV GP in virus-infected cells is controlled well by several mechanisms that do not allow GP overexpression and hence the early appearance of its cytotoxic properties.
BrayM.,
GeisbertT. W.2005; Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37:1560–1566[CrossRef]
ChanS. Y.,
MaM. C.,
GoldsmithM. A.2000a; Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 81:2155–2159
DolnikO.,
VolchkovaV.,
GartenW.,
CarbonnelleC.,
BeckerS.,
KahntJ.,
StroherU.,
KlenkH. D.,
VolchkovV.2004; Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23:2175–2184[CrossRef]
GeisbertT. W.,
HensleyL. E.,
JahrlingP. B.& 7 other authors2003a; Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362:1953–1958[CrossRef]
GeisbertT. W.,
YoungH. A.,
JahrlingP. B.,
DavisK. J.,
KaganE.,
HensleyL. E.2003b; Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188:1618–1629[CrossRef]
GeisbertT. W.,
YoungH. A.,
JahrlingP. B.,
DavisK. J.,
LarsenT.,
KaganE.,
HensleyL. E.2003c; Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163:2371–2382[CrossRef]
HarcourtB. H.,
SanchezA.,
OffermannM. K.1999; Ebola virus selectively inhibits responses to interferons, but not to interleukin-1 β , in endothelial cells. J Virol 73:3491–3496
ItoH.,
WatanabeS.,
SanchezA.,
WhittM. A.,
KawaokaY.1999; Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol 73:8907–8912
JasenoskyL. D.,
NeumannG.,
LukashevichI.,
KawaokaY.2001; Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 75:5205–5214[CrossRef]
MaruyamaT.,
RodriguezL. L.,
JahrlingP. B.,
SanchezA.,
KhanA. S.,
NicholS. T.,
PetersC. J.,
ParrenP. W.,
BurtonD. R.1999; Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73:6024–6030
RuthelG.,
DemminG. L.,
KallstromG.& 9 other authors2005; Association of Ebola virus matrix protein VP40 with microtubules. J Virol 79:4709–4719[CrossRef]
SanchezA.,
TrappierS. G.,
MahyB. W.,
PetersC. J.,
NicholS. T.1996; The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 93:3602–3607[CrossRef]
SimmonsG.,
Wool-LewisR. J.,
BaribaudF.,
NetterR. C.,
BatesP.2002; Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 76:2518–2528[CrossRef]
StroherU.,
WestE.,
BuganyH.,
KlenkH. D.,
SchnittlerH. J.,
FeldmannH.2001; Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75:11025–11033[CrossRef]
VarnavskiA. N.,
YoungP. R.,
KhromykhA. A.2000; Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol 74:4394–4403[CrossRef]
VolchkovV. E.,
BeckerS.,
VolchkovaV. A.,
TernovojV. A.,
KotovA. N.,
NetesovS. V.,
KlenkH. D.1995; GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214:421–430[CrossRef]
VolchkovV. E.,
FeldmannH.,
VolchkovaV. A.,
KlenkH. D.1998; Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 95:5762–5767[CrossRef]
VolchkovV. E.,
VolchkovaV. A.,
MuhlbergerE.,
KolesnikovaL. V.,
WeikM.,
DolnikO.,
KlenkH. D.2001; Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291:1965–1969[CrossRef]
VolchkovaV. A.,
FeldmannH.,
KlenkH. D.,
VolchkovV. E.1998; The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250:408–414[CrossRef]
WillC.,
MuhlbergerE.,
LinderD.,
SlenczkaW.,
KlenkH. D.,
FeldmannH.1993; Marburg virus gene 4 encodes the virion membrane protein, a type I transmembrane glycoprotein. J Virol 67:1203–1210
YangZ. Y.,
DuckersH. J.,
SullivanN. J.,
SanchezA.,
NabelE. G.,
NabelG. J.2000; Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6:886–889[CrossRef]
YeeJ. K.,
MiyanoharaA.,
LaPorteP.,
BouicK.,
BurnsJ. C.,
FriedmannT.1994; A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A 91:9564–9568[CrossRef]